News

First patient randomised in the phase III DISSOLVE clinical programme of SE L212 for chronic refractory gout.- SOBI + Selecta Biosciences

Read time: 1 mins

Published:24th Sep 2020

Swedish Orphan Biovitrum AB (publ) (Sobi) and Selecta Biosciences, Inc. announced the commencement of the phase III clinical programme of SEL 212 for chronic refractory gout, with the randomisation of the first patient in the study. .Sobi has in-licensed SEL 212 from Selecta and will be responsible for development, regulatory and commercial activities in all markets outside of China. The phase III programme for SEL 212 is being run by Selecta and funded by Sobi. Topline data from the phase III clinical programme is expected in the second half of 2022. Biologics license application (BLA) filing to the FDA for SEL 212 is expected in Q1, 2023.

Condition: Gout

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

Eli Lilly and Company announced positive topline results of the SURMOUNT-OSA phase III clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints

2 mins

Drug news

Topline results from phase II PRECEDENT study of dalzanemdor (SAGE 718) in the treatment of mild cognitive impairment in Parkinson’s disease

Sage Therapeutics, Inc. announced topline results from PRECEDENT, a double-blind, placebo-controlled Phase II study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson’s Disease (PD)

1 min

Drug news

Positive phase III topline results from Study 501 evaluating lumateperone as adjunctive therapy in patients with major depressive disorder

Intra-Cellular Therapies, Inc. a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

2 min

See all news